Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study

被引：0

作者：

Ines Zugasti ^{[1
]}

Monica Lopez-Guerra ^{[10
]}

Sandra Castaño-Díez ^{[12
]}

Daniel Esteban ^{[1
]}

Alejandro Avendaño ^{[11
]}

Helena Pomares ^{[13
]}

Ana Perez ^{[1
]}

Sara García-Ávila ^{[10
]}

Irene Padilla Conejo ^{[11
]}

Cristina de la Fuente Montes ^{[1
]}

Alexandra Martínez-Roca ^{[7
]}

Beatriz Merchán ^{[11
]}

Carlos Jiménez-Vicente ^{[2
]}

Francesca Guijarro ^{[10
]}

Jose Ramón Álamo ^{[3
]}

Albert Cortes-Bullich ^{[10
]}

Victor Torrecillas ^{[4
]}

Lucia Mont ^{[10
]}

Esther Carcelero ^{[5
]}

Gisela Riu ^{[10
]}

Lurdes Zamora ^{[6
]}

Joan Bargay ^{[10
]}

Ana Triguero ^{[7
]}

Maria Suarez-Lledó ^{[10
]}

Maria Queralt Salas ^{[1
]}

Felix López-Cadenas ^{[11
]}

Fernando Ramos ^{[1
]}

Blanca Xicoy ^{[11
]}

David Valcárcel ^{[1
]}

Montserrat Arnan ^{[11
]}

Carmen Martínez ^{[1
]}

Montserrat Rovira ^{[11
]}

Francesc Fernández-Avilés ^{[1
]}

Maria Díez-Campelo ^{[11
]}

Jordi Esteve ^{[1
]}

Marina Díaz-Beyá ^{[11
]}

机构：

[1] Hospital Clínic Barcelona,Institut Català d’Oncologia

[2] Hospital Universitario de Salamanca,Institut Català d’Oncologia (ICO)

[3] Hospital Duran I Reynals,undefined

[4] Hospital Universitario Vall d´Hebrón,undefined

[5] Hospital del Mar,undefined

[6] Hospital Universitario de León,undefined

[7] Hospital Germans Trias I Pujol,undefined

[8] Universitat de Barcelona,undefined

[9] Hospital Son Llátzer,undefined

[10] Grupo Español de Síndromes Mielodisplásicos (GESMD),undefined

[11] Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS),undefined

[12] Josep Carreras Leukemia Research Institute,undefined

[13] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),undefined

[14] Universitat Autònoma de Barcelona,undefined

来源：

Experimental Hematology & Oncology | / 14卷 / 1期

关键词：

MDS; CMML; MDS/MPN; Allo-SCT; Bridge therapy; Cytoreductive therapy; HMA/VEN; MRD; Molecular follow-up;

D O I：

10.1186/s40164-025-00652-5

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
Braish, Julie
Montalban-Bravo, Guillermo
Ravandi, Farhad
Short, Nicholas J.
Kadia, Tapan M.
Ohanian, Maro
Chien, Kelly S.
Masarova, Lucia
Sasaki, Koji
Yilmaz, Musa
Daver, Naval
Borthakur, Gautam
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2024, 144 : 3209 - 3210
[2] Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
Li, Chao
Deng, Chengxin
Wu, Ping
Liu, Kaifan
Huang, Xin
Li, Mingmin
Chen, Xiaomei
Geng, Suxia
Lai, Peilong
Weng, Jianyu
Du, Xin
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (01):
[3] Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study
Zugasti, Ines
Castano-Diez, Sandra
Esteban, Daniel
Avendano Pita, Alejandro
Pomares, Helena
Perez Gonzalez, Ana
Garcia-Avila, Sara
Padilla-Conejo, Irene
de la Fuente, Cristina
Martinez-Roca, Alexandra
Guijarro, Francesca
Alamo Moreno, Jose Ramon
Jimenez-Vicente, Carlos
Cortes-Bullich, Albert
Torrecillas, Victor
Guardia, Ares
Munarriz, Daniel
Carcelero, Esther
Suarez-Lledo, Maria
Queralt Salas, Maria
Lopez, Felix
Ramos, Fernando
Xicoy, Blanca
Valcarcel, David
Arnan Sangerman, Montserrat
Diez-Campelo, Maria
Martinez, Carmen
Rovira, Montserrat
Fernandez-Aviles, Francesc
Esteve, Jordi
Diaz-Beya, Marina
BLOOD, 2023, 142
[4] Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia
Kennedy, Vanessa E.
Hui, Gavin
Gaut, Daria
Mittal, Varun
Oliai, Caspian
Muffly, Lori S.
Logan, Aaron C.
Mannis, Gabriel N.
BLOOD, 2020, 136
[5] A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Short, Nicholas J.
Muftuoglu, Muharrem
Ong, Faustine
Nasr, Lewis
Macaron, Walid
Montalban-Bravo, Guillermo
Alvarado, Yesid
Basyal, Mahesh
Daver, Naval
Dinardo, Courtney D.
Borthakur, Gautam
Jain, Nitin
Ohanian, Maro
Jabbour, Elias
Issa, Ghayas C.
Qiao, Wei
Huang, Xuelin
Kanagal-Shamanna, Rashmi
Patel, Keyur P.
Bose, Prithviraj
Ravandi, Farhad
Delumpa, Ricardo
Abramova, Regina
Garcia-Manero, Guillermo
Andreeff, Michael
Cortes, Jorge
Kantarjian, Hagop
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[6] A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Nicholas J. Short
Muharrem Muftuoglu
Faustine Ong
Lewis Nasr
Walid Macaron
Guillermo Montalban-Bravo
Yesid Alvarado
Mahesh Basyal
Naval Daver
Courtney D. Dinardo
Gautam Borthakur
Nitin Jain
Maro Ohanian
Elias Jabbour
Ghayas C. Issa
Wei Qiao
Xuelin Huang
Rashmi Kanagal-Shamanna
Keyur P. Patel
Prithviraj Bose
Farhad Ravandi
Ricardo Delumpa
Regina Abramova
Guillermo Garcia-Manero
Michael Andreeff
Jorge Cortes
Hagop Kantarjian
Journal of Hematology & Oncology, 16
[7] Venetoclax Combined with Hypomethylating Agent (HMA) is Safe And Effective May Be A Good Bridge to Transplant in High-risk Acute Myeloid Leukemia
Federico, Vincenzo
Dargenio, Michelina
Matera, Rosella
Canaris, Angelodonato
Bozzoli, Valentina
Caretto, Vincenza
Carlino, Daniela
De Paolis, Maria Rosaria
Fina, Maria Paola
Loglisci, Giuseppina
Messa, Annarita
Reddiconto, Giovanni
Scardino, Stefania
Seripa, Davide
Soda, Annarosa
Vergine, Carolina
Di Renzo, Nicola
BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 28 - 29
[8] Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents
Kim, Gee Youn
Burns, Jonathan
Freyer, Craig W.
Hamilton, Keith
Schuster, Mindy
Frey, Noelle V.
Hexner, Elizabeth O.
Mangan, James K.
Martin, Mary Ellen
McCurdy, Shannon R.
Perl, Alexander E.
Porter, David L.
Luger, Selina
Loren, Alison W.
BLOOD, 2018, 132
[9] Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents
Kim, Gee Youn
Burns, Jonathan
Freyer, Craig W.
Hamilton, Keith W.
Frey, Noelle V.
Gill, Saar I.
Hexner, Elizabeth O.
Luger, Selina M.
Mangan, James K.
Martin, Mary E.
McCurdy, Shannon R.
Perl, Alexander E.
Porter, David L.
Schuster, Mindy G.
Stadtmauer, Edward A.
Loren, Alison W.
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (07) : 792 - 798
[10] VENETOCLAX PLUS AZACITIDINE VERSUS AZACITIDINE ALONE AS POST-TRANSPLANT MAINTENANCE TREATMENT IN HIGH-RISK AML AND MDS
Cao, Yigeng
Guo, Wenwen
Jiang, Erlie
BONE MARROW TRANSPLANTATION, 2024, 59 : 532 - 533

← 1 2 3 4 5 →